Business Description
PMV Pharmaceuticals Inc
NAICS : 541714
SIC : 2833
ISIN : US69353Y1038
Share Class Description:
PMVP: Ordinary SharesTotal Employee Number:
54Description
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 319.28 | |||||
Equity-to-Asset | 0.91 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 0.9 | |||||
3-Year EPS without NRI Growth Rate | 2.8 | |||||
3-Year FCF Growth Rate | 3.8 | |||||
3-Year Book Growth Rate | -28.5 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 14.25 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 63.52 | |||||
9-Day RSI | 56.57 | |||||
14-Day RSI | 51.25 | |||||
3-1 Month Momentum % | -8.89 | |||||
6-1 Month Momentum % | -0.81 | |||||
12-1 Month Momentum % | 13.89 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 11.14 | |||||
Quick Ratio | 11.14 | |||||
Cash Ratio | 10.88 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -5.2 | |||||
Shareholder Yield % | 10.03 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -63.76 | |||||
ROA % | -58.43 | |||||
ROIC % | -1139.93 | |||||
3-Year ROIIC % | 33.38 | |||||
ROC (Joel Greenblatt) % | -7788.31 | |||||
ROCE % | -67.82 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.72 | |||||
Price-to-Tangible-Book | 0.72 | |||||
EV-to-EBIT | 0.36 | |||||
EV-to-EBITDA | 0.36 | |||||
EV-to-FCF | 0.4 | |||||
| Price-to-Net-Current-Asset-Value | 0.73 | |||||
| Price-to-Net-Cash | 0.75 | |||||
Earnings Yield (Greenblatt) % | 277.78 | |||||
FCF Yield % | -118.2 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PMVP
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
PMV Pharmaceuticals Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.49 | ||
| Beta | 2.3656 | ||
| 3-Year Sharpe Ratio | -0.13 | ||
| 3-Year Sortino Ratio | -0.19 | ||
| Volatility % | 80.3 | ||
| 14-Day RSI | 51.25 | ||
| 14-Day ATR ($) | 0.069246 | ||
| 20-Day SMA ($) | 1.13625 | ||
| 12-1 Month Momentum % | 13.89 | ||
| 52-Week Range ($) | 0.9642 - 1.88 | ||
| Shares Outstanding (Mil) | 53.33 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
PMV Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
PMV Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 136 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 39 days | ||
| General meeting for 2026 | 2026-06-04 | 1.16 (-3.33%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 1.39 (-0.71%) | ||
| Annual report for 2025 | 2026-03-06 | 1.53 (+1.32%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-06 | 1.53 (+1.32%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-02 11:10 | 1.70 (+22.30%) | ||
| Third quarter earnings results for 2025 | 2025-11-12 | 1.33 (+2.31%) | ||
| Guidance call for 2025 | 2025-09-10 08:00 | 1.60 (+12.68%) | ||
| Second quarter earnings results for 2025 | 2025-08-07 | 1.52 (+3.40%) |
Show
Entries
PMV Pharmaceuticals Inc Frequently Asked Questions
What is PMV Pharmaceuticals Inc(PMVP)'s stock price today?
The current price of PMVP is $1.19. The 52 week high of PMVP is $1.88 and 52 week low is $0.96.
When is next earnings date of PMV Pharmaceuticals Inc(PMVP)?
The next earnings date of PMV Pharmaceuticals Inc(PMVP) is 2026-08-07 Est..
Does PMV Pharmaceuticals Inc(PMVP) pay dividends? If so, how much?
PMV Pharmaceuticals Inc(PMVP) does not pay dividend.
Guru Commentaries on NAS:PMVP
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator | 2024-05-29 |
Articles on PMV Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers